Clinical Trial Update: Evaluate the Safety and Tolerability, as Well as the Pharmacokinetic and Pharmacodynamic Profiles of Single and Multiple Doses of Eplontersen Administered Subcutaneously to Healthy Volunteers and Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR ). [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple subcutaneous doses of eplontersen in healthy volu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Transthyretin-mediated Amyloidosis

Drugs mentioned

• Eplontersen (eplontersen)

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Healthy Volunteers, hATTR Amyloidosis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-12-19